Abcellera posts ABCL635 Phase 2 clinical update presentation on menopause hot flashes
Reuters2026/08/10 11:39- Abcellera released a Phase 2 clinical update presentation for ABCL635 in moderate-to-severe menopausal vasomotor symptoms.
- Week 4 data showed an 83% reduction in moderate-to-severe VMS frequency vs. 33% for placebo; placebo-adjusted difference 50%.
- VMS severity score fell 58% vs. 12% for placebo at week 4; placebo-adjusted difference 46%.
- Safety summary showed no serious or grade 3+ adverse events in the ABCL635 arm; one mild transaminase increase resolved within one week.
- Next steps include completing 12-week follow-up to support dose selection, then regulatory talks on late-stage development in menopause and oncology settings.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pi Network’s PI Defends a Critical Support, Bitcoin (BTC) Reclaims $78K: Weekend Watch
Pons: $20.93 million has been paid to token creators over the past 47 days
XRP’s Crazy August Is Almost Over – September Could Be Even Bigger
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Crypto prices
More
